Malena Cohen-Cymberknoh1, Noa Gilead2, Silvia Gartner3, Sandra Rovira3, Hannah Blau4, Huda Mussaffi4, Joseph Rivlin5, Michal Gur5, Michal Shteinberg5, Lea Bentur6, Galit Livnat6, Micha Aviram7, Elie Picard8, Ariel Tenenbaum9, Shoshana Armoni1, Oded Breuer1, David Shoseyov1, Eitan Kerem1. 1. CF Center, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 2. Medical School, Hebrew University, Jerusalem, Israel. 3. CF Center, Hospital Universitari Vall d' Hebron, Barcelona, Spain. 4. Graub CF Center, Schneider Children's Medical Center, Petach Tikva and Sackler Faculty of Medicine, Tel-Aviv University,Israel. 5. CF Center, Carmel Medical Center, Haifa, Israel. 6. CF Center, Rambam Medical Center, Haifa, Israel. 7. CF Center, Soroka Medical Center, Beer-Sheva, Israel. 8. Pediatric Pulmonary Unit, Shaare-Zedek Medical Center, Jerusalem, Israel. 9. Department of Pediatrics, Hadassah-Hebrew University Medical Center, Mount Scopus, Jerusalem, Israel.
Abstract
Eradication of Pseudomonas aeruginosa (PA) is critical in cystic fibrosis (CF) patients. OBJECTIVES: To determine eradication success rate of newly acquired PA and to identify characteristics associated with eradication failure. METHODS: In an observational study, data from patients with newly acquired PA infection from 2007 to 2013 were collected. Clinical variables were compared in patients with and without successful eradication for ≥1year. RESULTS: Of 183 patients out of 740 (25%) from 7 CF Centers that had newly acquired PA, eradication succeeded in 72%. Patients with the highest risk of failure had multi-resistant PA, fewer sputum cultures taken, were older, and were diagnosed at a later age. The risk of eradication failure increased by 1.3% with each year of delayed CF diagnosis; successful eradication increased by 17% with each additional sputum culture taken. CONCLUSIONS: Delayed detection of PA infection leading to delayed treatment and growth of multi-resistant organisms is associated with eradication failure. Copyright Â
Eradication of Pseudomonas aeruginosa (PA) is critical in cystic fibrosis (CF) patients. OBJECTIVES: To determine eradication success rate of newly acquired PA and to identify characteristics associated with eradication failure. METHODS: In an observational study, data from patients with newly acquired PA infection from 2007 to 2013 were collected. Clinical variables were compared in patients with and without successful eradication for ≥1year. RESULTS: Of 183 patients out of 740 (25%) from 7 CF Centers that had newly acquired PA, eradication succeeded in 72%. Patients with the highest risk of failure had multi-resistant PA, fewer sputum cultures taken, were older, and were diagnosed at a later age. The risk of eradication failure increased by 1.3% with each year of delayed CF diagnosis; successful eradication increased by 17% with each additional sputum culture taken. CONCLUSIONS: Delayed detection of PA infection leading to delayed treatment and growth of multi-resistant organisms is associated with eradication failure. Copyright Â
Authors: Giovanni Taccetti; Michela Francalanci; Giovanna Pizzamiglio; Barbara Messore; Vincenzo Carnovale; Giuseppe Cimino; Marco Cipolli Journal: Antibiotics (Basel) Date: 2021-03-22
Authors: Jonathan D Cogen; Frankline M Onchiri; Nicole Mayer Hamblett; Ronald L Gibson; Wayne J Morgan; Margaret Rosenfeld Journal: Clin Infect Dis Date: 2021-09-15 Impact factor: 9.079
Authors: Nicole Mayer-Hamblett; George Retsch-Bogart; Margaret Kloster; Frank Accurso; Margaret Rosenfeld; Gary Albers; Philip Black; Perry Brown; AnneMarie Cairns; Stephanie D Davis; Gavin R Graff; Gwendolyn S Kerby; David Orenstein; Rachael Buckingham; Bonnie W Ramsey Journal: Am J Respir Crit Care Med Date: 2018-11-01 Impact factor: 30.528